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THE aim of the study was to analyse the effect of
interleukin-4 (IL-4) on allergen and anti-IgE
mediated histamine release from basophils and
human skin mast cells and to assess whether
soluble recombinant interleukin-4 receptor (sIL-
4R) can inhibit these effects. Anti-IgE stimulated
histamine release from peripheral blood baso-
phils and mast cells of atopic donors was en-
hanced after preincubation with IL-4, whereas
after preincubation with sIL-4R it was inhibited.
These effects were even more pronounced when
samples were stimulated with a clinically relevant
allergen. In IL-4 preincubated skin mast cells,
there was a similar enhancement of anti-IgE
stimulated histamine release, which could again
be inhibited by sIL-4R. The effects of IL-4 and sIL-
4R were dose- and time-dependent. Mice sensi-
tized to ovalbumin and treated with soluble
recombinant murine sIL-4R showed signi￿ cantly
reduced immediate-type cutaneous hypersensitiv-
ity responses compared with untreated mice.
These in vivo effects were IgE independent, since
there were no signi￿ cant differences in total and
allergen speci￿ c IgE/IgG1 antibody titres between
treated and untreated mice. This indicates that IL-
4 exerts priming effects on histamine release by
effector cells of the allergic response and that
these effects are potently antagonized by soluble
IL-4R both in vitro and in vivo.
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Introduction
Interleukin-4 (IL-4) plays a central role in
allergic in￿ammation.1 It acts as an important
immunoglobulin isotype switch factor for IgE
synthesis and is required for initiation and
promotion of a TH2 T -cell response.2 5 IL-4
stimulates expression of endothelial cell adhe-
sion molecules on lymphocytes,6 eosinophils,
basophils and mast cells.7 9 IL-4 production is
increased in atopic dermatitis patients10 and IgE
synthesis induced by IL-4 is enhanced during
seasonal allergen exposure.11
While there is clear evidence of IL-4 produc-
tion by T -lymphocytes, some reports raise the
possibility of IL-4 production by human mast
cells12,13 and basophils.14 Furthermore, human
mast cells express IL-4 receptors.15 Mast cells
and basophils represent important effector cells
of the immediate-type allergic response which
is characterized by the release of histamine and
other mediators upon cross-linking of receptor
bound IgE molecules by allergens. The expres-
sion of IL-4 receptors on these cells suggests
that mast cells and basophils are sensitive to
this cytokine. Since little is known about the
interaction of IL-4 with effector cells, we
examined the potential role of IL-4 on allergen
and anti-IgE triggered histamine release from
human basophils and skin mast cells. We
examined further whether immunomodulation
with an IL-4 antagonist would inhibit the IL-4
mediated effects. It has recently been shown
that a recombinant soluble IL-4 receptor can
inhibit many of the IL-4 mediated cell functions
both in vitro and in vivo.16,17 To examine the
biological relevance of these ￿ndings, allergen
sensitized mice were treated with a murine
recombinant soluble IL-4 receptor and the
immediate skin response was assessed.
Material and Methods
Patients
For experiments on basophils, blood was drawn
from 11 adult atopic patients (six women, ￿ve
men), aged 20± 44 years (mean age 33 years).
Mediators of In¯ ammation ´ Vol 6 ´ 1997 111T otal IgE ranged from 45 to 6650 kU/l (median
429 kU/l). Patients were sensitive to birch
pollen (Betula verrucosa) (Bet v) and/or Der-
m atophagoides pteronyssinus (Der p). Sensiti-
zation was proven by speci￿c IgE to birch and/
or house-dust mite in serum (Pharmacia CAP-
system, Uppsala, Sweden). Blood was taken
over all the year except during the seasons
April/May for birch- and September/October for
house dust mite-sensitive patients. All patients
suffered from allergic rhinoconjunctivitis, one
patient from atopic dermatitis as well. All pa-
tients were without any anti-allergic medication
for at least 4 weeks before drawing blood for
the experiments. No patient had any infection
during 2 weeks before the study.
Mast cells were prepared from normal human
breast skin of six healthy female donors, aged
21± 45 years (mean age 29 years), with no
history of atopy who were undergoing plastic
surgery for cosmetic reasons. All patients gave
their informed consent. The study was ap-
proved by the local ethics committee.
Reagents and buffer solutions
The following reagents were purchased: pipes,
collagenase type 1a, hyaluronidase type I-S,
chicken ovalbumin (OVA) grade V , (Sigma,
Deisenhofen, Germany), Dextrane 6% (Braun,
Melsungen, Germany), glucose 40%(Fresenius,
Bad Homburg, Germany), perchloric acid
(Merck, Darmstadt, Germany), allergen extract
from Der p and Bet v (ALK, Copenhagen,
Denmark), IL-4 (Dianova, Hamburg, Germany),
DNAse (Boehringer, Mannheim, Germany), IgE,
HSA (Pfrimmer, Erlangen, Germany), MEM
(Earle’s salts, fetal calf serum (FCS) (Gibco,
Berlin, Germany), anti-IgE (Behring, Marburg,
Germany); Pipes A (with 0.025% HSA), Pipes
EDTA (Pipes A with 4 mM EDTA), and Pipes
ACM (Pipes A with 2 mM CaCl2 and 0.5 mM
MgCl2) were used in all experiments at a pHof
7.40. In experiments with human skin mast
cells, MEM culture medium was supplemented
with 2% FCS, 1% penicillin and streptomycin,
1%glutamine, 2%MgSO4 and 10 mg/ml DNAse.
Human and murine recombinant
soluble IL-4 receptor
Soluble IL-4 receptor was prepared as pre-
viously described.18 Brie￿y, using cDNA for the
extracellular region of human and murine IL-
4R,19,20 recombinant soluble monomeric forms
of IL-4R (human, rhuIL-4R and murine, muIL-
4R) were constructed. The murine and human
forms of rIL-4R were expressed in BHK cells.
The proteins were puri￿ed by af￿nity chromato-
graphy using speci￿c antibodies. Bioactivity,
glycosylation and pharmacokinetics in mice
were controlled for each lot of the molecules to
achieve an uniform reactivity in vitro and in
vivo.
Preparation of basophil cultures from
peripheral blood
Basophils were enriched and cultivated as
previously described.21 Brie￿y, peripheral blood
leukocytes were obtained by spontaneous sedi-
mentation for 60 min at room temperature. The
percentage of viable basophils within the leuko-
cyte preparation ranged between 6%and 11% .
Cells were washed twice with Pipes A/EDTA
and centrigued for 10 min. 1 3 107 leukocytes
were placed in 4 ml plastic tubes (Sarstedt,
Nu ¨mbrecht, Germany) in Pipes EDTA buffer.
Cells were preincubated with IL-4 (100 to
5000 IU/ml), sIL-4R (1 to 200 mg/ml) or buffer
in a water bath at 378 C for 2.5 h. After decant-
ing supernatants and washing cells in Pipes A,
Pipes ACMwas added and cells were challenged
with anti-IgE(30 and 100 IU/ml), Der p (30 and
100 SQ/ml) or Bet v (22 and 220 ng/ml). After a
30 min incubation at 378 C, cells were centri-
fuged for 15 min and supernatants were stored
at 208 C until determination of histamine. All
measurements were performed in duplicate.
Preparation of human skin mast cells
cultures
Mast cells were isolated by enzymatic disper-
sion, with slight modi￿cation as previously
described.22 Brie￿y, skin was cut into small
squares (1± 2 mm2), dispersed in two 1-h cycles
with collagenase and hyaluronidase (15 mg and
7.5 mg/g tissue respectively, 2.5 ml medium/g
tissue). Undissociated tissue was removed by
￿ltration with nylon gauze (150 mm) and there-
after the cells were washed twice in Pipes A.
Viability of mast cells was determined by trypan
blue staining and mast cell purity was assessed
by toluidine blue staining. Viability of mast cells
was . 95% . This procedure yielded 6 8 3 105
mast cells/g wet tissue with 3± 5%mast cells of
total nucleated cells. After collection of the
dissociated cells, these were washed twice with
Pipes A and then passively sensitized with IgE
(1 mg/106 cells) at room temperature overnight.
The cells were then incubated in Pipes ACM
with 10± 1000 ng/ml IL-4 for 5± 15 min at 378 C
in a water bath, or overnight in medium in an
incubator. Aliquots of 104 mast cells in 0.4 ml
pipes ACM were challenged in duplicate with
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0.417 IUprecipitating 1 ng IgEWHOstandard).
Measurement of histamine release
Spontaneous histamine release, which was de-
termined by the addition of Pipes ACMinstead
of stimuli, ranged between 5%and 10%of total
histamine content. T otal cellular histamine con-
tent was assayed by lysis of cell aliquots with
2%perchloric acid. After a 20 min incubation at
378 C, cells were centrifuged and supernatants
were stored at 208 Cuntil analysed.
Histamine was determined with an automated
￿uorometric analyser (Technicon, New York,
USA) using a procedure previously described.23
Results were only considered where sponta-
neous histamine release was less than 10% of
total histamine content. More than 80%of our
experiments ful￿lled the criteria. For each
result, spontaneous histamine release (incuba-
tion in Pipes ACM buffer) was subtracted and
calculated as a percentage of total histamine
content ( 100% ) for each culture condition.
The measurements were performed in dupli-
cate.
Allergic sensitization of mice
BALB/c mice (aged 6± 10 weeks, from Bomholt-
gard, Denmark) were sensitized to OVA by
nebulization of 1%ovalbumin (OVA) diluted in
PBS. Sensitization was performed by exposure
for 20 min every seventh day. As previously
shown24 and con￿rmed in this study, this
procedure stimulated production of allergen-
speci￿c IgE/IgG1. After 4 weeks, mice were
treated ￿ve times every other day by 20 min
nebulization of 1 mg sIL-4R diluted in 7 ml PBS.
Skin testing was performed 24 h after the last
treatment. The study was approved by the local
Animal Ethics Committee.
Assessment of immediate-type skin
tests response in mice
Intradermal skin tests (ST) were performed as
previously described.25 Brie￿y, abdominal skin
was shaved and 50 ml of test solution was
injected intradermally. PBS was used as negative
control and compound 48/80 (Sigma, Mu ¨nchen,
Germany) as positive control. Injection points
were separated by at least 1.5 cm in order to
avoid con￿uence of solutions. Allergen concen-
tration was 50 mg/ml for ovalbumin. Resultant
wheal formations were scored in a blinded
fashion after 15± 20 min by semiquantitative
assessment of skin test reactivity. Reactions with
a diameter < 1 mm were scored with 0 points,
2± 4 mm with 1 point and reactions > 5 mm
with 2 points. All animals developed positive
wheal formations to compound 48/80, none
reacted to PBS.
Measurement of total and allergen-
speci® c IgE/IgG1 antibody titres in
serum samples
Analysis of total IgE and anti-OVA IgE/IgG1
antibody titres were determined by ELISA.
Brie￿y, 96-well U-bottom, polystyrene microtitre
plates (Greiner, Nu ¨rtingen, Germany) were
coated either with anti-mouse IgE (10 mg/ml)
(Pharmingen, San Diego, USA) or ovalbumin
(20 mg/ml) Sigma, Deisenhofen, Germany) di-
luted in 0.05 M carbonate coating buffer, pH
9.6. Plates were incubated overnight, washed
three times in washing buffer (PBS/0.05%plus
Tween 20, pH8.2) and blocked for 2 h at 378 C
with blocking solution (2% BSA in PBS). After
three washes with washing buffer, samples
diluted in PBS/0.4%BSA were incubated for 2 h
at 378 C. Washed plates were incubated with
biotin-conjugated anti-mouse IgE/IgG1 mono-
clonal antibodies for 2 h at 378 C (2.5 mg/ml)
(Pharmingen, San Diego, USA) followed by
incubation with alkaline phosphate-conjugated
streptavidin (1:500) (Jackson Immuno Research
Laboratories, West Grove, USA) for 1 h at 378 C.
Plates were developed with p-NPP substrate
(0.5 mg/ml) (Sigma, Deisenhofen, Germany)
and absorbance was measured at 405 nm.
Statistical analysis
For statistical analysis, we used the Wilcoxon
test for paired data, and Mann-Whitney U-test.
For all numbers, standard error of mean is
given. P values , 0 05 were considered as
statistically signi￿cant.
Results
Modulation of histamine release by
human basophils
In order to investigate the effect of IL-4 on
histamine release from human basophils, cells
were stimulated with anti-IgE or the clinically
relevant allergens. After preincubation with
buffer alone, both anti-IgE and allergen en-
hanced histamine release in a dose-dependent
manner, with a peak release at 100 IU/ml for
anti-IgE (percentage of total histamine over
background release 32 8% 4% ). The optimal
concentration of allergen ranged at 22 ng/ml for
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ground release 40 8% 4% ) and 100 standard
quantity units (SQU)/ml for Der p (percentage
of total histamine over background release
27 0% 3% ). Using concentrations lower than
22 ng/ml Bet v or 100 SQU/ml Der p, less
pronounced histamine release was measured,
which was not signi￿cantly different from con-
trols (data not shown).
Cells were preincubated with IL-4 for 2.5 h
followed by stimulation with optimal doses of
anti-IgE and allergen. IL-4 enhanced anti-IgE
triggered histamine release by 9 5% 1 4%(Fig.
1). However, IL-4 by itself was unable to induce
histamine release in the absence of any stimu-
lus. A more pronounced effect was observed on
allergen-triggered mediator release. Increases of
histamine release by up to 35%were measured,
with a percentage total histamine over back-
ground release of 19 0% 6% . The reason why
we converted the data into values of percentage
stimulation/inhibition was the interindividual
variability of the patients. We did not ￿nd major
differences between Bet v and Der p effects in
our culture system. For this reason, and because
the individual groups would have been too
small, we decided to present the results of both
allergens together in one ￿gure.
Since histamine release by peripheral blood
basophils was analysed in the presence of cell
subsets capable of secreting IL-4, and since
enhanced IL-4 production has been demon-
strated by peripheral blood lymphocytes from
atopic donors,10,11,26 it was necessary to deter-
mine whether intrinsic ongoing IL-4 production
contributed to the priming effect observed in
the assay. A soluble recombinant human IL-4
receptor (sIL-4R) was added to cultures prior to
stimulation with anti-IgE or allergen. Histamine
release in peripheral blood basophils stimulated
with anti-IgE was inhibited after preincubation
with sIL-4R by 7 9 6 5% (Fig. 1). An even
more pronounced reduction was measured
when cells were stimulated with allergen (Der
p): sIL-4R inhibited histamine release by up to
20% , with a mean reduction of 11 3 3 2%
(Fig. 1). This data provides evidence that
intrinsic ongoing IL-4 secretion by peripheral
blood leukocytes exerts priming effects on
histamine release by basophils.
Dose-response experiments showed that the
effects of IL-4 (Fig. 2A) and sIL-4R (Fig. 2B) on
both anti-IgE and allergen induced histamine
release were dependent on the concentration.
However, despite a clear tendency, results failed
to reach statistical signi￿cance due to small
numbers in some concentrations. Maximal aug-
mentation of histamine release was found fol-
lowing preincubationwith more than 1000 U/ml
IL-4; sIL-4R at a concentration of . 100 mg ml
resulted in optimal inhibition of histamine
release. To assess the speci￿city of these effects,
cells were preincubated with a murine recombi-
nant soluble IL-4R that does not bind to human
IL-4. Incubation of leukocytes with murine sIL-
4R in the same dose range was without any
effects on anti-IgE or allergen-induced mediator
release (data not shown).
Optimal effects were achieved when cells
were preincubated with IL-4 and sIL-4R for
about 2.5 h. Preincubation for a shorter period
decreased the priming effect of IL-4 (data not
shown). When cells were preincubated for a
period longer than 3.5 h, spontaneous hista-
mine release signi￿cantly (P, 0 05) increased
and interfered with the assessment of IL-4/sIL-
4Reffects.
Modulation of histamine release from
human skin mast cells
T o analyse whether IL-4 would also exert prim-
ing effects on other effector cells of the allergic
reaction, we examined the effect of IL-4 on
mast cells prepared from human non-atopic
skin. Mast cells were presensitized with human
IgE and in vitro histamine release was mea-
sured following stimulation with anti-IgE. There
was a signi￿cant (P, 0 05) enhancement of
n 5  8 n 5  11 n 5  8 n 5  10
P ,  0.02
P ,  0.05 P ,  0.008
P ,  0.02
P ,  0.0004 P ,  0.0004
IL-4 IL-4 sIL-4R sIL-4R
anti-IgE allergen
0
10
20
30
2 10
2 20
% histamine release
FIG. 1. Effect of IL-4 and sIL-4R on histamine release by
peripheral blood basophils. Cells of atopic patients were
preincubated with or without either IL-4 (5000 U/ml) or sIL-
4R (200mg/ml) for 2.5 h followed by stimulation with either
anti-IgE or allergen. Mean percentage of total histamine
over background release of anti-IgE stimulated cells was
32.8%, and 40.8% in allergen stimulated experiments. For
each experiment, the percentage of stimulation/inhibition
was calculated. Expressed are mean standard error of
mean values. Experiments were performed with allergic
patients; numbers are indicated in the ® gure. P-values
around the baseline indicate statistical signi® cance in rela-
tion to baseline values.
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1 9%to 8 3% 1 9% ) following preincubation
with IL-4 (Fig. 3). This could be blocked by
simultaneous addition of sIL-4R(n 2, data not
shown).
Inhibition of immediate-type
cutaneous hypersensitivity responses
by treatment with sIL-4R
The previous results indicate a priming effect of
IL-4 and an inhibitory effect of sIL-4R on in
vitro histamine release. The biological relevance
of these ￿ndings was evaluated using an animal
model of allergic sensitization and IgE
production.27 BALB/c mice were locally sensi-
tized to ovalbumin via the airways. It has been
shown that this procedure results in an increase
of allergen-speci￿c IgE/IgG1, development of
positive skin test responses and enhanced air-
way responsiveness.25 The mice were sensitized
to OVA for 4 weeks followed by a brief period
of treatment with murine sIL-4R also via the
airways. The development of allergen speci￿c
cutaneous hypersensitivity responses was then
assessed by intradermal injection of allergen as
described above. As shown in Fig. 4, mice
sensitized to OVAvia airways and treated by the
same route with sIL-4R developed signi￿cantly
smaller wheal responses than mice that were
anti-IgE allergen
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FIG. 2. Stimulation by IL-4 and inhibition by sIL-4R of
histamine release. Cells from atopic patients were preincu-
bated with or without IL-4 (100 to 5000 U/ml) (A) or sIL-4R
(1± 200 mg/ml) (B) for 2.5 h followed by stimulation with
anti-IgE (100 IU/ml) and allergen (22 ng/ml Bet v and
100 SQ/ml Der p). A total of seven patients was analysed.
For each donor, stimulation and inhibition of histamine
release were compared with incubation with buffer alone
and results are expressed in percentage changes. Expressed
are mean standard error of mean values.
Pipes A IL-4 (10ng/ml)
anti-IgE (4000IU/ml)
0
5
10
15
% histamine release from skin mast cells
P ,  0.05
FIG. 3. IL-4 enhances anti-IgE induced histamine release
from skin mast cells. Mast cells were prepared from the skin
of non-atopic individuals (n 6) and sensitized with human
IgE. Cells were then preincubated with either Pipes A buffer
or IL-4 (10 ng/ml) followed by stimulation with anti-IgE
antibodies (4000 IU/ml). Expressed are mean standard
error of mean values of histamine release. Histamine
release was assessed and calculated as described in Mater-
ial and Methods.
0
0.5
1
1.5
2
P ,  0.07 NS
sIL-4R sIL-4R
OVA
(n 5  8) (n 5  8)
Co 48/80
2 2 1 1
Skin test score (points)
FIG. 4. Skin test response in sIL-4R treated and untreated
mice. Mice were sensitized to OVA by aerosolization, then
treated with sIL-4R via the same route (as described in
Material and Methods) and skin tests were performed with
OVA, compound 48/80 and PBS. Resultant wheal formations
were scored in a blinded manner and results are expressed
as mean standard error of mean values.
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of in vivo mediator release was selective, since
wheal formations stimulated by administration
of compound 48/80 were not affected. Further-
more, these effects were not related to inhibi-
tion of IgE/IgG1 production by sIL-4R, since
total and allergen speci￿c IgE/IgG1 concentra-
tions were the same in untreated OVA-sensitized
animals (Table 1).
Discussion
This study provides evidence that IL-4 primes
effector cells of the allergic response to release
histamine upon stimulation with allergen and
anti-IgE. With allergen as the trigger factor for
histamine release, mediator release was found
to increase by up to 35% . These ￿ndings were
supported by a similar and signi￿cant effect on
the development of in vivo immediate-type
cutaneous hypersensitivity responses. These
results point to a novel function of IL-4.
IL-4 interferes with the allergic response at
several levels of regulation: it is associated with
the development of Th2 type T -lymphocytes
and acts as a growth factor for Th2 cells;2 5 it
stimulates IgE synthesis3 5 and is involved in
mast cell activation.7 9 IL-4 is produced by T -
lymphocytes and effector cells including baso-
phils and mast cells.12,13 The results of this study
indicate that the functional role of IL-4 in
allergic in￿ammatory responses is not restricted
to the development of pro-allergic T - and B-cell
functions. It also interferes during the effector
phase of the allergic response by priming
mediator secretion from basophils and mast
cells. We measured histamine release by these
effector cells, since it represents an important
and clinically relevant mediator of the early
phase of the immediate-type allergic response.
It is likely that secretion of other mediators
which are released together with the prototypic
mediator histamine is also enhanced under the
in￿uence of IL-4.
Since there is increasing evidence for the
secretion of IL-4 by mast cells and basophils,28,29
one can envisage a multidirectional activity of
IL-4 during the development of immediate-type
I allergic reactions. If IL-4 is released upon
crosslinking of membrane-bound IgEantibodies,
this source of IL-4 may prime neighbouring
effector cells to release higher amounts of
histamine (and other mediators). Therefore, IL-4
would potentiate the development of the aller-
gic response in an autocrine and paracrine
fashion. In our experiments it is possible that
preactivated mast-cells and/or basophils were
the source of IL-4 production.
Exactly how IL-4 primes effector cells re-
quires further clari￿cation. It is possible that it
triggers the release of preformed mediators
which are stored in cytoplasmic vesicles. Since
IL-4 acts relatively quickly (the priming effects
reached optimal levels within 2.5 h) it is un-
likely that IL-4 increases histamine synthesis by
regulation of transscriptional and/or transla-
tional events.
In skin mast cells, histamine releasability is
generally lower than in basophils.30 The en-
hancement of anti-IgEinduced histamine release
observed here was in the range of 4.5%mean
histamine release before and 8.3%after pretreat-
ment with IL-4. Although these differences may
appear low, this represents an 80%increase of
histamine release, which could be biologically
relevant considering that the differences ob-
served in anti-IgE induced basophil histamine
release between normal controls and asthmatics
appear low as well (median histamine release
20%vs. 26% ).31
The effects of IL-4 were inhibited in vitro and
in vivo by a recombinant soluble IL-4 receptor.
W e have shown in a previous study that
treatment with sIL-4R can inhibit many IL-4
mediated functions under certain experimental
conditions.32 For example, when BALB/c mice
were treated with sIL-4Rsimultaneously to aller-
gen sensitization, it inhibited the development
of IgE/IgG1 production and therefore the induc-
tion of immediate-type allergic reactions, includ-
ing postive immediate-type skin test responses,
and also increased airway responsiveness. We
concluded from that study that the effects of
sIL-4R treatment were related to a functional
interference at the level of T± B cell interaction.
T o study whether sIL-4R would also act directly
on the effector phase of the allergic response,
we modi￿ed the sensitization and treatment
protocol. Sensitized mice were treated with the
receptor via nebulization for a short time prior
to analysis of skin test reactivity. In the present
study, the drug was delivered via the airways
since it has recently been shown that local
administration was superior to systemic treat-
Table 1. Serum total IgE, anti-OVA IgE and anti-OVA IgG1
in mice treated with sIL-4R in comparison with untreated
animals (n 16). Results (day 36) are expressed as mean
SD
Treatment
sIL-4R
Treatment
sIL-4R
P
Total IgE (O.D.) 0.31 0.17 0.29 0.19 NS
Anti-OVA IgE (O.D.) 0.27 0.10 0.24 0.10 NS
Anti-OVA IgG1 (O.D.) 0.41 0.36 0.41 0.35 NS
O.D. optical density.
116 Mediators of In¯ ammation ´ Vol 6 ´ 1997
B. Niggem ann et al.ment in terms of the inhibitory effects of
immediate hypersensitivity responses.33
It is unlikely that the in vivo effects of sIL-4R
in our study design were due to down-regula-
tion of IgE/IgG1 production, because mice were
already sensitized at the time the treatment was
started and because the treatment was carried
out over a short period of time. In addition, it is
likely that Ig was already bound to IgEreceptors
on effector cells and it is suggested that
receptor bound IgE has a long half-life time. In
fact, measurement of IgE/IgG1 antibody titres
indicated that there were no differences be-
tween sIL-4R treated and untreated mice. It is
therefore likely that the effects observed in
treated mice were related to a down-regulation
of histamine release. SIL-4R treated mice still
developed wheal formations immediately fol-
lowing allergen application into the skin, but
the wheals were signi￿cantly smaller to a
degree that re￿ects the results of the in vitro
experiments. However, it should also be consid-
ered that IgE-mediated allergic sensitization to
systemic allergen can occur in the absence of
circulating IgE. In addition, a direct correlation
exist between increased IgE production and
mast cell activation.
In conclusion, this study provides evidence
for a new functional activity of IL-4 as a
cytokine which primes effector cells of the
allergic response to release histamine upon
stimulation with allergen. This activity under-
scores the important and multidirectional activ-
ities of this cytokine in the regulation of many
aspects of the immunopathogenesis of allergic
in￿ammatory responses. IL-4 not only controls
the development of pro-allergic T -cell functions
and triggers production of IgE, but also acts on
effector cells of the allergic response. The
biological relevance of these functions was
demonstrated in sensitized mice which were
treated with recombinant murine sIL-4R. The
treatment study elucidated two important as-
pects: ￿rstly, the development of in vivo
immediate cutaneous hypersensitivity responses
is directly controlled by IL-4, and, secondly, sIL-
4R represents a potent immuno-pharmaco-
logical inhibitor for this (and other) functional
activities of IL-4.
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